CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in ...

CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

(Source: GDTC Form 20-F) In my opinion, of all of CytoMed’s programs, this product platform has the most potential to become a pipeline in a product. By combining the properties of γδ T cells and NK ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

GDTC is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of GDTC shares has decreased $0.04 since the market last closed. This is a 3.87% ...